AURKA and cancer: AURKA overexpression has been identified in several types of cancer (including GBM) as a driver of chromosomal instability and consequent aneuploidy; seventeen patients were enrolled (11 GBM) starting from the initial cohort of 20 mg BID to the final cohort of 50 mg BID, all with concurrent FSRT (35 Gy in 3.5 Gy fractions): 6 m-OS for all the cohort was 88.2% and median OS was 11.1 m; 6 m-PFS was 35.3% with an mPFS of 4.9 m.